SCHEMBL8312795

SCHEMBL8312795

CCCCN1CCN(CCOC(C)=O)CC1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.55
▸ SLC18A3 Q16572 1/20 0.48
▸ HRH1 P35367 7/20 0.44
▸ HRH2 P25021 6/20 0.44
▸ PAOX Q6QHF9 1/20 0.41
▸ USP2 O75604 1/20 0.40
▸ TSHR P16473 1/20 0.39
▸ GNAI3 P08754 1/20 0.39
▸ GNAO1 P09471 1/20 0.39
▸ GNAI1 P63096 1/20 0.39
▸ SLC29A1 Q99808 2/20 0.39
▸ S1PR1 P21453 1/20 0.38
▸ S1PR3 Q99500 1/20 0.38
▸ S1PR5 Q9H228 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9660752 0.93 ALDH1A1 (0.52) ALDH1A1SLC18A3HRH1HRH2PAOX
SCHEMBL9328257 0.88 — —
SCHEMBL20609092 0.88 SLC18A3 (0.56) ALDH1A1SLC18A3HRH1PAOXTSHR
SCHEMBL15224088 0.87 SLC18A3 (0.47) ALDH1A1SLC18A3HRH1HRH2PAOX
SCHEMBL8148114 0.85 SLC18A3 (0.50) ALDH1A1SLC18A3HRH1TSHRSLC29A1
SCHEMBL13674269 0.84 DGKA (0.59) ALDH1A1HRH1HRH2TSHR
SCHEMBL11858444 0.82 SLC18A3 (0.51) ALDH1A1SLC18A3PAOXTSHRSLC29A1
SCHEMBL14500225 0.82 SLC18A3 (0.51) ALDH1A1SLC18A3TSHRSLC29A1
SCHEMBL15224086 0.82 ALDH1A1 (0.50) ALDH1A1SLC18A3HRH1HRH2TSHR
SCHEMBL13236346 0.81 SLC18A3 (0.50) ALDH1A1SLC18A3TSHRSLC29A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299043-A1 Anti-scarring drug combinations and use thereof HUNTER WILLIAM L 2007-12-27 — — US disclosed
US-20070299043-A1 Anti-scarring drug combinations and use thereof HUNTER WILLIAM L 2007-12-27 — — US disclosed
US-20070208134-A1 Anti-scarring drug combinations and use thereof HUNTER WILLIAM L 2007-09-06 — — US disclosed
US-20070208134-A1 Anti-scarring drug combinations and use thereof HUNTER WILLIAM L 2007-09-06 — — US disclosed
US-20070196421-A1 Soft tissue implants and drug combination compositions, and use thereof ANGIOTECH INTERNATIONAL AG (CH) 2007-08-23 — — US disclosed
US-20070196421-A1 Soft tissue implants and drug combination compositions, and use thereof ANGIOTECH INTERNATIONAL AG (CH) 2007-08-23 — — US disclosed
US-20070198063-A1 Electrical devices and anti-scarring drug combinations HUNTER WILLIAM L 2007-08-23 — — US disclosed
US-20070198063-A1 Electrical devices and anti-scarring drug combinations HUNTER WILLIAM L 2007-08-23 — — US disclosed
US-20070197957-A1 Implantable sensors, implantable pumps and anti-scarring drug combinations HUNTER WILLIAM L 2007-08-23 — — US disclosed
US-20070197957-A1 Implantable sensors, implantable pumps and anti-scarring drug combinations HUNTER WILLIAM L 2007-08-23 — — US disclosed
WO-2007041677-A9 SOFT TISSUE IMPLANTS AND DRUG COMBINATION COMPOSITIONS, AND USE THEREOF COMBINATORX INC (US) 2007-05-31 — — WO disclosed
US-20070099906-A1 Combinations for the treatment of noeplastic disorders COMBINATORX, INC. 2007-05-03 — — US disclosed
US-20070099906-A1 Combinations for the treatment of noeplastic disorders COMBINATORX, INC. 2007-05-03 — — US disclosed
WO-2007041584-A2 IMPLANTABLE SENSORS, IMPLANTABLE PUMPS, AND ANTI-SCARRING DRUG COMBINATIONS COMBINATORX, INCORPORATED (US) 2007-04-12 — — WO disclosed
WO-2007041463-A2 ELECTRICAL DEVICES AND ANTI-SCARRING DRUG COMBINATIONS COMBINATORX, INCORPORATED (US) 2007-04-12 — — WO disclosed
WO-2007041677-A2 SOFT TISSUE IMPLANTS AND DRUG COMBINATION COMPOSITIONS, AND USE THEREOF COMBINATORX, INCORPORATED (US) 2007-04-12 — — WO disclosed
WO-2007041593-A2 ANTI-SCARRING DRUG COMBINATIONS AND USE THEREOF COMBINATORX, INCORPORATED (US) 2007-04-12 — — WO disclosed
WO-2004073614-A2 COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS COMBINATORX, INCORPORATED (US) 2004-09-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099906-A1 Combinations for the treatment of noeplastic disorders NOP56, XPOT, NPM1 ALDH1A1 1322/4885SLC18A3 3633/4885HRH1 3631/4885
US-20070208134-A1 Anti-scarring drug combinations and use thereof MMP1, COL2A1, COL1A1 ALDH1A1 590/4885SLC18A3 2944/4885HRH1 2332/4885
US-20070196421-A1 Soft tissue implants and drug combination compositions, and use thereof COL2A1, MMP1, FN1 ALDH1A1 1623/4885SLC18A3 3053/4885HRH1 2342/4885
US-20070299043-A1 Anti-scarring drug combinations and use thereof MMP1, COL2A1, COL1A1 ALDH1A1 590/4885SLC18A3 2944/4885HRH1 2332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback